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The family Legionellaceae consists of Gram-negative bacteria that are widely distributed in aquatic environ-
ments around the world. This family consists of a single genus, Legionella, that is recognized as an important
cause of community-acquired pneumonia and hospital-acquired pneumonia. Legionella consists of intracellular
pathogens, thus cellular pharmacokinetic and pharmacodynamic properties of an antibiotic against these bac-
teria as well as uptake and subcellular distribution into macrophages should be considered for a successful
outcome of disease. Treatment strategies for Legionella infection require a combination of multiple antibiotics.
Hence, because of the possible development of resistance to the drugs during therapy, a new alternative targeted
therapy is yielding promising results. In this study, a comprehensive in silico target identification pipeline was
performed on members of the family Legionellaceae to identify the best targets. Using a homology-based
computational pipeline method, new drug targets were identified. Of 4,358 analyzed proteins, 18 proteins,
including proteins involved in metabolism (amino acid, energy, and lipid metabolisms), cellular transport, cell
division, and cell motility, were selected as the final putative drug targets. These proteins play an important role
in the survival and propagation of Legionella infection. In conclusion, homology-based methods could improve
the identification of novel drug targets and the drug discovery process, which can potentially be effective for the
prevention and treatment of Legionella infections.
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Introduction
The family Legionellaceae consists of the singlegenus Legionella. The common characteristic of these
bacteria is that they are Gram-negative bacteria, obligate
aerobes, and nonspore-forming rod-shaped cells.1 The
number of recognized species and serogroups of the genus
Legionella continues to increase over recent years. Members
of this genus were initially isolated from a wide range of
natural and artificial aquatic environments, and also most
species are motile and have maximum three polar flagella.1–3
Several species have been recognized as pathogenic for
humans and this can lead to Legionellosis infection varying
in severity from mild febrile disease of influenza-like
(Pontiac fever) to a potentially fatal form of pneumonia
(Legionnaires’ disease).4,5
Pneumonia due to Legionella infection is an important
public health problem that is frequently caused by Legio-
nella pneumophila with either community- or hospital-
acquired Legionellosis. Therefore, this organism has the
potential to cause both outbreaks and sporadic cases.5,6 The
fatality rates associated with Legionnaires’ disease among
untreated patients are*15–20%.7 Owing to the small size of
Legionella and adaptation to intracellular compartments, an
appropriate treatment of the antimicrobial agents is crucial for
a successful outcome of Legionnaires’ disease; on this basis,
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intracellular penetration, accumulation, and distribution are
important parameters to the activity of antibiotics against
intracellular bacteria.8 Thus, antimicrobial agents with ade-
quate intracellular penetration into alveolar macrophages as
well as subcellular compartments are more effective than
antibiotics with poor intracellular penetration.
There are several major classes of antibiotics, including
macrolides, fluoroquinolones, tetracyclines, rifamycins, and
ketolides, which are used for the treatment of Legionella
infections.5,7 Because of the ability of Legionella spp. to
survive and multiply in human macrophages, consequently,
like other intracellular pathogens, antibiotics that penetrate
cell membrane are drugs of choice. Aminoglycosides in
general are too water soluble and penetration into biologic
membranes is poor; therefore, they are taken up slowly by
endocytosis, which results in an exclusively lysosomal lo-
calization. Whereas both macrolides and fluoroquinolones
accumulate in phagocytes. In addition, some drugs are
quickly cleared from phagocytes, consequently their con-
centration and intracellular distribution vary because of
differences in their intracellular pH gradients of the cytosol
and subcellular compartments.7,8
On the contrary, treatment ofLegionella infection requires a
combination of multiple antibiotics, thus this may pose a
concern on the development of drug resistance during therapy.
In recent years, several cases of drug resistance to routinely
prescribed antimicrobials in Legionella isolates have been
reported, among which L. pneumophila strains were more
resistant than other Legionella species.7,9–14 It is very impor-
tant to note that hidden resistance cases have also been
reported and have been suggested to be correlated with treat-
ment failure and poor prognosis in Legionnaires patients.15
The current strategies to identify drug targets are rela-
tively difficult, time consuming, and expensive, often re-
sulting in very finite drug targets.16–18 Furthermore, the
stages of drug discovery and development using traditional
methods are a linear multistep process and yield few drug
targets with little feedback from intracellular information for
guiding target selection. Therefore, with the arrival of ge-
nome research during the past decade, focus on drug de-
velopment has shifted to computational comparative
genomics to identify novel drug targets.16,19
In silico drug target identification, which includes a series of
algorithms to identify genes and proteins, is applied to the
discovery and development of potential therapeutic targets.
These approaches increase the efficiency of therapeutic targets,
reduce timelines and costs of the drug discovery process, and
also provide a closer look of the entire microorganism. Speed,
low cost, and, even more importantly, providing a systematic
view of the whole microorganism are the advantages of
in silico techniques for identification and validation of drug
targets. These features provide a great chance for asking
questions that are often difficult to address experimentally.
There has been an increase in the use of in silico identification
methods to find drug targets in several studies.17,18,20,21
With the help of genome-sequencing projects of pathogens
and humans, microbial drug target identification has been
revolutionized in recent years. Among genomic strategies,
subtractive genomics has been successfully used in the iden-
tification of microbial drug targets.22 Various methods can be
used to discover a proper therapeutic target such as compara-
tive genomics models,23 structure and sequence to func-
tion,24,25 metabolic pathways,26 and data mining.27 The most
used methods to identify new therapeutic targets are based on
the sequence similarity using the Basic Local Alignment
Search Tool (BLAST) algorithm.28 In this study, a similarity-
basedmethodwas used for genome-wide prediction of the drug
targets in major pathogens of the family Legionellaceae, con-
sidering theL. pneumophila str. Paris as an important pathogen.
Materials and Methods
Step I
The complete proteome of L. pneumophila str. Paris that
comprises 3,012 chromosomal proteins and 134 plasmid
proteins was downloaded from the National Center for
Biotechnology Information (NCBI) genome database.
Virulence Factor Database (VFDB) is a practical database
of virulence factors (VFs) for bacterial pathogens and
also Chlamydia and Mycoplasma. All the major VFs of
L. pneumophila str. Paris (127 proteins) were retrieved from
VFDB. All literature reported that L. pneumophila str. Paris
resistance proteins were downloaded from NCBI.21,29 Using
the Search Tool for the Retrieval of Interacting Genes/
Proteins (STRING) 10.0 tool and seven active prediction
methods (neighborhood, gene fusion, co-occurrence, coex-
pression, experiments, databases, and text mining), inter-
action partners of L. pneumophila str. Paris resistance
proteins with high confidence value (0.7) were predicted.
The protein sequences of resistance genes and their partners
were retrieved from NCBI and STRING database. Finally, a
comparative metabolic pathway was performed to analyze
between L. pneumophila str. Paris and human as the host.
All the proteins in the different pathways of L. pneumophila
str. Paris and unique proteins of L. pneumophila str. Paris
were collected in common pathways (between L. pneumo-
phila str. Paris and human). All proteins in the different
pathways of human and unique proteins of human in common
pathways were excluded. The amino acid sequences of the
selected proteins were downloaded from the Kyoto En-
cyclopedia of Genes and Genomes (KEGG) and NCBI. Total
proteins of step I (Greenlist) were transferred to step II.
Step II
Host homology search. Themain goal of this step is to find
proteins in L. pneumophila str. Paris that have no similarity to
the human proteome. This analysis minimizes the undesirable
side effects of the drug.21,30 The Greenlist proteins were sub-
jected to BLASTp against nonredundant protein sequences of
human (taxid: 9606) with an e-value of 0.005.21,30,31 The
Greenlist proteins that showed no hits for the 0.005 e-value
were transferred to the next test (the test of essentiality).
Test of essentiality. The proteins in Greenlist were ex-
amined to recognize essential proteins using BLASTp
search against DEG, a database of essential genes. The DEG
BLASTp expected value cutoff was adjusted to 10-5. The
hits with less than e-value of 10-5, identity ‡25%, and same
annotated function of the query were selected as essential
proteins.21,30,32 The proteins in Greenlist that revealed hits
with DEG BLASTp parameters were collected and trans-
ferred to the next step (gastrointestinal flora homology test).
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The other proteins that revealed no hit in DEG BLASTp
were excluded from the analysis.
Homology search for gastrointestinal flora. Unintentional
targeting of vital molecules in the gut microorganisms may
cause harmful effects on the host. To prevent this condition,
a custom database was created from gut microflora reported
in the literature and the proteins of Greenlist were subjected
to BLASTp search against this custom database with an
expected threshold of 10-4.17,20,21,32 The Greenlist proteins
that showed >10 hits were excluded and the rest were se-
lected as Whitelist. The Whitelist comprises the primary
potential drug targets of L. pneumophila str. Paris.
Step III
Whole proteome comparisons. To find similarities, the
proteome of important pathogens of the family Legionella-
ceae was compared. All proteomes belonging to these path-
ogens were compared in TaxPlot with a cutoff value of 200.
Homology search for Legionellaceae. To find homologues
in important pathogens of the family Legionellaceae, primary
potential drug targets of L. pneumophila str. Paris in Whitelist
were subjected to BLASTp against a custom database. The
BLASTp was done with an expected value of 10-4. Proteins
with identity ‡50% were selected as final potential drug tar-
gets in the family Legionellaceae (Redlist) and were quali-
tatively characterized using various tools in step IV.
Step IV
The biological function of an unknown protein in the
Redlist (hypothetical proteins) was determined by means of
Pfam tool. Subcellular localization sites of some proteins
were recognized in the literature, and web-based tools, such
as Prediction of Subcellular Localization of bacterial pro-
teins. (PSLpred), Prediction of Protein SORTing (PSORT),
and subcellular localization predictor (CELLO), were used to
predict possible subcellular localization sites of Redlist pro-
teins. PSLpred is a web server that uses Support Vector
Machines (SVMs) to predict protein subcellular localiza-
tion.33 PSORT is a computer program for the prediction of
protein localization sites in cells.34 CELLO is a web server
for protein subcellular localization prediction and functional
gene ontology analysis.35 In the broad-spectrum search, a
custom database of bacterial pathogens reported in the liter-
ature was created.20 Proteins in Redlist were evaluated using
BLASTp search against a custom database with an e-value of
0.005 for the identification of broad-spectrum targets. In the
DrugBank database,36 Redlist proteins were subjected to
BLASTp search with an e-value of 10-5. The presence of
molecule with the same biological function in BLAST results
shows the druggability of the target molecules, and absence
shows the novelty of the target molecules.21,32
Results
In this study, a subtractive homology-based method was
used to identify a collection of potential therapeutic targets
in some bacterial pathogens of the family Legionellaceae. A
systematic pipeline that involved several computational
tools and databases was developed (Fig. 1). Only these
proteins were selected as acceptable drug targets that suc-
cessfully passed the pipeline.
Step I
In the complete proteome (chromosomal and plasmid) of
L. pneumophila str. Paris, 1,589 proteins were produced by
positive strand and 1,557 proteins were translated from
negative strand. Distributions of the protein lengths in the
L. pneumophila str. Paris proteome were in the range of 44–
7,679 amino acids. All 3,146 L. pneumophila str. Paris pro-
teins were transferred to the next step. The major VFs in L.
pneumophila str. Paris have been divided into the following
seven groups: adherence, intracellular survival, invasion, iron
acquisition, regulation, secretion systems, and toxins. All
VFs (127 proteins) were transferred to step II. Inhibition of
VFs proteins could reduce the virulence of pathogenic bac-
teria. Nine proteins that confer resistance to antimicrobial
drugs in L. pneumophila str. Paris were obtained from the
literature and corresponding sequences were retrieved from
NCBI. Using STRING 10.0 tool and seven active prediction
methods (neighborhood, gene fusion, co-occurrence, coex-
pression, experiments, databases, and text mining) with a
high confidence value (0.7), 342 interaction partners for
resistance-causing proteins were predicted. Antimicrobial
resistance proteins and their interaction partners are consid-
ered as potential drug targets and suppression of these pro-
teinsmay block the antimicrobial resistance process.20 All the
antimicrobial resistance proteins and their interaction part-
ners (351 proteins) were transferred to the next step. In the
KEGG database, there are 299metabolic pathways for human
and 109 metabolic pathways for L. pneumophila str. Paris.
Pathways of L. pneumophila str. Paris are classified as me-
tabolism, genetic data processing, environmental data pro-
cessing, and cellular processes. Of 109metabolic pathways in
L. pneumophila str. Paris, 30 pathways were unique and 79
pathways were common with humans. Sequences of 531
unique proteins from common pathways and 203 proteins
from distinct pathways were selected and transferred to step
II. Finally, 4,358 proteins, including chromosomal and plas-
mid proteome, VFs, resistance proteins and their interaction
partners, and common and unique metabolic pathway pro-
teins were collected as Greenlist and transferred to step II.
Step II
A collection of 4,358 proteins that resulted from step I
(Greenlist) were subjected to three sequential BLAST sear-
ches to find primary targets (Fig. 1). The first and third
BLAST searches determined the proteins that were nonho-
mologous to human and gut microflora proteome. The es-
sentiality of the proteins was assessed by second BLAST
search against a known set of essential proteins in DEG da-
tabase. Targeting of the proteins homologous to host by drug
compounds could adversely alter the host metabolism.
Therefore, filtering proteins homologous to human proteome
is considered in several computational drug target discovery
methods.17,21,30,32 A total of 4,358 L. pneumophila str. Paris
proteins, including chromosomal and plasmid proteome
(3,146 proteins), pathogenicity islands and VFs (127 pro-
teins), resistance proteins and their interaction partners (351
proteins), and common and unique metabolic pathway pro-
teins (734 proteins), were subjected to host homology search
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FIG. 1. The complete flowchart of the homology-based method.
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against the whole protein of the human. Proteins without any
hits in BLAST search were considered as nonhomologous,
whereas those showing hits were regarded as homologous. Of
the 4,358 input proteins, 802 proteins that showed no hits
against human proteome were selected and 3,556 proteins
(homologous to human proteome)were excluded from the next
step of the analysis. Essential genes are the genes of an or-
ganism that are vital for its survival. To preserve the vital
process of an organism such as central metabolism, DNA
replication, translation, cellular structure maintenance, and
cellular transport, essential genes produce proteins. A drug
target must be an essential protein for the survival of patho-
genic microorganisms. Targeting of such proteins could cause
growth inhibition and disrupt biological functions of micro-
organism. The Greenlist proteins were analyzed for determi-
nation of essentiality using DEG 11.3 database. Of 802 input
proteins, 464 proteins were identified to be essential for the
pathogen and selected for the next analyses. In addition, 338
proteins that showed no hits against DEG (nonessential) were
excluded from the analysis. The gut microbiota plays an es-
sential role in human metabolism, physiology, and nutrition,
and it also plays an essential role in human health bypreventing
pathogens from colonization. Therefore, the decay of the gut
microbiota population may cause problems in human
health.37,38 The essential resulting proteins from previous an-
alyseswere subjected toBLASTp against a customdatabase of
the whole proteome of gut microbiota. Of 464 input proteins,
60 proteins were collected as Whitelist and 404 proteins
showing >10 hits were excluded. Whitelist proteins were se-
lected as primary potential drug target of L. pneumophila str.
Paris and were used for the next step of the analysis.
Step III
The reference proteome of L. pneumophila str. Paris was
compared with the family Legionellaceae pathogens to find
similarities. The Whitelist was subjected to BLASTp against
a custom database of the family Legionellaceae pathogens
from 60 proteins in the Whitelist. Eighteen proteins that
showed identity ‡50% were selected as Redlist (Table 1).
Redlist proteins were taken as the final potential drug targets
in the family Legionellaceae (Table 2). The Redlist consists
of proteins involved in metabolism, cellular transport, cell
division, and cell motility. Proteins involved in metabolism
and cellular transport provide a major contribution to the
Redlist of final targets (13 of 18 proteins). Targets involved
in multiple metabolic pathways are thought to be a more
efficient drug target, and preventing the activity of such
targets could increase lethal effects by blocking the activity
of several metabolic pathways of the microorganism. Of the
18 Redlist targets, 8 targets (lpp0252, lpp0381, lpp1542,
lpp1671, lpp1673, lpp2256, lpp2454, and lpp2758) were in-
volved in >1 metabolic pathway (Table 2).
Step IV
In this step, Redlist proteins were further explored using
various analyses (functional search, subcellular localization
search, broad-spectrum search, and druggability search)
(Fig. 1). The biological function of unknown and hypo-
thetical proteins in Redlist was determined by using Pfam
tool. Eight proteins in Redlist, namely, lpp0375, lpp1542,
lpp1720, lpp1729, lpp1975, lpp2256, lpp2683, and lpp2758
were unknown and hypothetical (Table 2). Hypothetical
protein lpp0375 was determined to be an OstA-like protein.
The OstA protein is known as an organic solvent tolerance
protein.39 Hypothetical protein lpp1542 was predicted to be
a CDP-alcohol phosphatidyl transferase (CDP-AP). Phos-
pholipids have key roles in the structure and function of
all cell membranes. Members of CDP-alcohol phospho-
transferase family are integral membrane proteins which are
all involved in phospholipid biosynthesis. They catalyse
the displacement of cytidine monophosphate (CMP) from
a CDP-alcohol by a second alcohol with formation of a
phosphodiester bond and concomitant breaking of a phos-
phoride anhydride bond.40 Hypothetical protein lpp1720
was determined to be a flagellar FliJ protein, this family is
found in bacterial motility proteins in flagellar system.
Hypothetical protein lpp1729 was predicted to be an outer
membrane (OM) lipoprotein carrier protein LolA that plays
in the translocation of lipoproteins from the inner membrane
(IM) to the OM.41 Hypothetical protein lpp1975 was de-
termined to be membrane-bound lytic transglycosylase
(MltA)-specific insert domain. This beta barrel domain is
found inserted into the MltA, a murein-degrading enzyme.
This domain that contains three conserved aspartate residues
may be involved in peptidoglycan binding.42 Hypothetical
protein lpp2256 was predicted to be a preprotein translocase
subunit SecB. SecB is a cytoplasmic module common with
membrane-bound multisubunit enzyme termed Sec protein
translocase, which is the main component of the general
secretory pathway (type II), involved in translocation of
aborning polypeptides across the cytoplasmic membrane.43
Hypothetical protein lpp2683 was determined to permease
the YjgP/YjgQ family. Members of this family are integral
membrane proteins of unknown function. Finally, hypo-
thetical protein lpp2758 was predicted to be the cytochrome
C1 family, which is the third complex in the electron
transport chain. To identify cellular localization, Redlist
proteins were analyzed using PSORT, PSLpred, and CEL-
LO tools. In PSORTb and PSLpred, based on the localiza-
tion score, reliability index, and expected accuracy, five
targets were predicted to be cytoplasmic proteins, five tar-
gets were predicted to be cytoplasmic membrane proteins,
two targets were predicted to be periplasmic, and two targets
were predicted to be the OM protein. The cellular locali-
zation of four targets (lpp0252, lpp0922, lpp1673, and
lpp2664) was predicted to be unknown. Furthermore, to
obtain greater accuracy, the predicted subcellular localiza-
tion of the targets was cross-evaluated using the CELLO
tool. In CELLO, the location of six targets was determined
as cytoplasmic, the location of two targets was determined
Table 1. Number of Proteins Used
in the Performed Analyses
Analysis
Input
proteins
Output
proteins
Failed
proteins
Host homology search 4,358 802 3,556
Test of essentiality 802 464 338
Gastrointestinal flora homology
search
464 60 404
Legionellaceae homology
search
60 18 42
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as periplasmic, the location of nine targets was determined
as IM, and the location of one target was determined as OM.
Of the four targets characterized as unknown by PSORTb
and PSLpred, one target was predicted as cytoplasmic, one
target was predicted as periplasmic, and two targets were
predicted as IM (Table 3). Six proteins with cytoplasmic
localization and nine proteins with IM localization and one
protein with OM localization could, respectively, possibly
serve as drug and vaccine targets (Table 3). In a broad-
spectrum search, BLASTp against a custom database of the
whole proteome of bacterial pathogens resulted in the rec-
ognition of broad-spectrum targets. Results of the broad-
spectrum search showed that 7, 8, and 3 targets were present
in >100 pathogens, between 50 and 100 pathogens, and <50
pathogens, respectively. Seven proteins of Redlist that were
present in >100 pathogens were considered as broad-
spectrum targets (Table 3). Drug targets involved in vital
metabolic process seem to be a broader spectrum than the
other targets such as VFs. VFs are not often broad-spectrum
drug targets because of high specificity. Targeting of broad-
spectrum proteins by drug molecules may facilitate the de-
struction of a wide range of pathogenic bacteria. One target
that is present in <25 pathogens was considered as the
family Legionellaceae-specific targets. Such specific target
proteins may decrease the threat of antimicrobial resistance
development in a wide range of pathogenic bacteria.20
Druggability search was the final analysis in this approach.
Druggability of Redlist targets was assessed using BLASTp
against DrugBank database. Similarity search showed that
four targets (lpp0252, lpp1671, lpp1673, and lpp2454) are
homologous to each other or more known targets in DrugBank
database with an expected value of 10-5. BLASTp against
DrugBank also showed that the lpp0252 target has three ex-
perimental inhibitors [2-amino-3-(1-hydroperoxy-1 h-indol-3-
yl) propan-1-ol, ethionamide, and isoniazid], lpp1671 has one
experimental inhibitor (formic acid), lpp1673 has two experi-
mental inhibitors (N*2*-succinylarginine and N*2*
-succinylornithine), and lpp2454 has three experimental in-
hibitors [2-amino-3-(1-hydroperoxy-1 h-indol-3-yl) propan-1-
ol, ethionamide, and isoniazid]. All these four druggable
targets are involved in vital pathways of amino acid metabo-
lism of L. pneumophila str. Paris. Fourteen targets, showing no
homology with DrugBank database, were considered as novel
drug targets, which should be further evaluated experimentally
(Table 3).
Discussion
Recent advances in whole genome sequencing and com-
putational methods have facilitated the discovery of novel
antimicrobial agents and could enable us to combat antibi-
otic resistance in bacteria. In addition, they have provided
Table 2. List of Putative Drug Targets in the Legionellaceae Family
No. Description NCBI accession KEGG ID
KEGG
pathway ID Length, aa
1 Catalase peroxidase CAH11399 lpp0252 lpp01100 749
lpp01110
lpp00360
lpp00380
2 Hypothetical protein lpp0375 CAH11523 lpp0375 No hits! 839
3 Preprotein translocase secE CAH11529 lpp0381 lpp0381 123
lpp0381
4 Heme exporter protein CcmC CAH12071 lpp0920 lpp02010 251
5 Cytochrome c-type biogenesis protein CcmE CAH12073 lpp0922 No hits! 143
6 Hypothetical protein lpp1542 CAH12693 lpp1542 lpp00564 255
lpp01110
7 Arginine N-succinyltransferase, beta chain CAH12823 lpp1671 lpp00330 346
lpp01100
8 Succinylarginine dihydrolase CAH12825 lpp1673 lpp00330 448
lpp01100
9 Septum formation topological specificity factor CAH12842 lpp1690 No hits! 89
10 Hypothetical protein lpp1720 CAH12872 lpp1720 lpp02040 151
11 Hypothetical protein lpp1729 CAH12881 lpp1729 No hits! 202
12 Hypothetical protein lpp1975 CAH13127 lpp1975 No hits! 398
13 Hypothetical protein lpp2256 CAH13409 lpp2256 lpp03060 162
lpp03070
14 Catalase-peroxidase KatB CAH13607 lpp2454 lpp01100 721
lpp01110
lpp00360
lpp00380
15 Cell division protein FtsQ CAH13817 lpp2664 No hits! 239
16 Hypothetical protein lpp2683 CAH13836 lpp2683 lpp02010 359
17 Hypothetical protein lpp2758 CAH13911 lpp2758 lpp01100 248
lpp00190
lpp02020
18 Putative TatA protein (twin arginine translocation) CAH14126 lpp2973 lpp03060 61
lpp03070
aa, amino acid; NCBI, National Center for Biotechnology Information; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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important insights into the molecular mechanisms of un-
derlying diseases. The development of new bioinformatic
approaches and modulation and optimization of existing
strategies can increase the accuracy of drug target identifi-
cation.44 This study has shown how bioinformatics and
in silico approaches can be used in the drug discovery
processes. As biological systems are complex networks of
many metabolic and nonmetabolic pathways, the explana-
tion of such systems may be obtained by considering large-
scale studies. Focusing on a single drug target at a time in
conventional drug discovery methods may not always pro-
duce acceptable or expected results. Comprehensive study
of biological pathways and whole cell systems provides
wider insights into the fitness of a potential drug target.
Some proteins in an organism that may be predicted as good
drug targets, when viewed in the context of a biological
system, may not actually be vital. Analyzing drug targets in
the context of a biological system can help in evaluating the
criticality of the individual targets in the cell pathways. Of
4,358 proteins analyzed, 18 (Redlist) were selected as final
putative drug targets in the family Legionellaceae (Table 2).
Putative targets were filtered to exclude nonviable candi-
dates based mostly on importance of survival, lack of ho-
mology to the human host, well-known biological function,
and conserved between Legionellaceae species. The Redlist
consists of proteins involved in metabolism (amino acid,
energy, and lipid metabolisms), cellular transport, cell di-
vision, and cell motility. These essential genes that play a
great role in cell survival encode the proteins to control a
central metabolism, replicate DNA, translate genes into
proteins, maintain a basic cellular structure, and mediate
transport processes within or out of the cell.45 The essential
proteins are involved in many biological pathways that
represent molecular interaction networks between the
pathogen and the host. Essentiality search shows some vital
proteins that are required by the pathogen to perform im-
portant roles for their survival, growth, and replication.
Therefore, a broader search of bioinformatics is a critical
stage to predict potential drug target in the pathogens.
Proteins involved in metabolism and cellular transport
provide a major contribution to the Redlist of final targets
(14 of 18 proteins). Of the 18 Redlist protein targets, 8
targets (lpp0252, lpp1542, lpp1671, lpp1673, lpp2256,
lpp2454, lpp2758, and lpp2973) are involved in >1 meta-
bolic pathway (Table 2). Restricted targeting of some spe-
cific pathways may cause development of multidrug
resistance among pathogenic bacteria.21 In general, ap-
proaches that consider all essential pathways of organisms
can be more successful to identify efficient drug targets.
Targets involved in multiple metabolic pathways are
thought to be a more efficient drug target, and preventing the
activity of such targets could increase lethal effects by
blocking the activity of several metabolic pathways of the
microorganism. Targeting of metabolic enzymes for cancer
therapy is a hot topic for drug discovery.46 Molecular
structures of membrane transporter proteins are significant
for drug discovery. These proteins are important coplayers
in cellular systems and are known molecular components of
many disease processes. The membrane transporter proteins
are targeted by many currently used drugs and have a major
potential as targets for new drug development. A large
number (60–70%) of the current known drug targets are
proteins set in a cellular membrane, and membrane proteins
are among the most interesting macromolecules to study us-
ing structural biology techniques. High-resolution structural
knowledge about proteins placed in a cellular membrane is
Table 3. Qualitative Characterization of Putative Drug Targets
No. NCBI ID KEGG ID Function prediction
Subcellular
localization
Broad-spectrum
condition Druggability
1 CAH11399 lpp0252 Not required Periplasmic Yes Druggable
2 CAH11523 lpp0375 OstA-like protein/
organic solvent tolerance protein
Outer membrane Yes Novel
3 CAH11529 lpp0381 Not required Inner membrane No Novel
4 CAH12071 lpp0920 Not required Inner membrane No Novel
5 CAH12073 lpp0922 Not required Inner membrane No Novel
6 CAH12693 lpp1542 CDP-alcohol
phosphatidyltransferase
Inner membrane No Novel
7 CAH12823 lpp1671 Not required Cytoplasmic Yes Druggable
8 CAH12825 lpp1673 Not required Cytoplasmic No Druggable
9 CAH12842 lpp1690 Not required Cytoplasmic No Novel
10 CAH12872 lpp1720 Flagellar FliJ protein Cytoplasmic No Novel
11 CAH12881 lpp1729 Outer membrane lipoprotein
carrier protein LolA
Cytoplasmic Yes Novel
12 CAH13127 lpp1975 MltA-specific insert domain/
3D domain
Inner membrane Yes Novel
13 CAH13409 lpp2256 Preprotein translocase
subunit SecB
Cytoplasmic No Novel
14 CAH13607 lpp2454 Not required Periplasmic Yes Druggable
15 CAH13817 lpp2664 Not required Inner membrane No Novel
16 CAH13836 lpp2683 Predicted permease YjgP/
YjgQ family
Inner membrane Yes Novel
17 CAH13911 lpp2758 Cytochrome C1 family Inner membrane No Novel
18 CAH14126 lpp2973 Not required Inner membrane No Novel
MltA, membrane-bound lytic transglycosylase; CDP, cytidine diphosphate.
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not only of pivotal importance for developing new drugs with
therapeutic potential, but is also necessary for the knowledge
of the molecular mechanisms of cellular signaling and func-
tion.47 The lpp2758 target is involved in the bacterial two-
component system. By using the two-component system, the
pathogens perceive the changes in the environment and re-
spond to it.Moreover, involvement in the pathogenicity of the
organisms and the absence of these systems in humans make
them attractive drug targets.48 Therefore, inhibition of these
proteins can reduce the growth rate and virulence of the
pathogen. Targeting of proteins involved in DNA replication,
DNA repair, DNA recombination, and cell division (lpp2664
and lpp1690)may disrupt the pathways essential for pathogen
survival, growth, and reproduction. Seven broad-spectrum
targets are involved in crucial processes such as cellular
transport, environmental information processing, and me-
tabolism (Tables 2 and 3). Drug targets involved in the vital
metabolic process seem to have a broader spectrum than the
other targets such as VFs. Because of high specificity, VFs are
not often broad-spectrum drug targets. Targeting of broad-
spectrum proteins by drug molecules may facilitate the de-
struction of a wide range of pathogenic bacteria. Eleven
Legionellaceae-specific targets are suitable for the develop-
ment of narrow-spectrum antibiotic. Such specific target
proteins may decrease the threat of development of antimi-
crobial resistance in a wide range of pathogenic bacteria.
Based on the localization analysis, most targeting proteins
were located in the membrane (Table 3). Inhibition of target
proteins located on themembrane and extracellular proteins is
important because of their crucial role as VFs assisting
pathogens to spread and proliferate within the host. Knowl-
edge of protein localization is valuable for learning the
function and the interaction of different proteins. When other
information is not available, the subcellular localization will
also be effective in the annotation for new proteins. In drug
discovery process, subcellular localization data can help un-
derstand therapeutic intervention points. For example, be-
cause of their localization, secreted proteins and membrane
proteins are easily available by drug molecules.49 The Gram-
negative bacteria are surrounded by two membranous struc-
tures, the IM and the OM. The IM that is called the plasma
membrane has a trilamellar structure surrounded with bac-
terial protoplasm and composed of a phospholipids bilayer.
Most of the membrane proteins that have role in energy
production, lipid biosynthesis, protein secretion, and trans-
port system are conserved in bacteria, but their cellular lo-
cation is different. In bacteria, these proteins are located in the
IM.50,51 The OM also presents a trilamellar structure (with
couple electron dense leaflets, outer and inner) in the electron
micrograph and consists of proteins, containing porins, re-
ceptors, and an asymmetric distribution of lipids.50 The OM
of Gram-negative bacteria provides a difficult barrier that
must be overcome. There are essentially two pathways that
antibiotics can take within the OM: a lipid-mediated pathway
for hydrophobic antibiotics and general dissemination porins
for hydrophilic antibiotics, which consequently may lead to
antibiotic resistance.52 Druggability refers to the ability of a
target molecule to bind with high affinity to the drug mole-
cules. Druggability is one of the most important characteris-
tics of a target molecule. Four druggable targets (lpp0252,
lpp1671, lpp1673, and lpp2454) are involved in vital process
such as oxidant–antioxidant system, metabolism, and bio-
synthesis of macromolecule. Either of these proteins is a
target for conventional antibiotics. Fourteen novel drug tar-
gets are suitable for development of new antimicrobials and
should be further evaluated experimentally. Currently, sev-
eral computational methods such as comparative genomics,
data mining, structure and sequence to function, and meta-
bolic pathways are used for the identification and character-
ization of the drug targets. Most of these target discovery
methods enable us to identify potential drug target candidates
based on the main criteria of specificity and essentiality.
Besides these properties, a suitable drug target must be spe-
cific to the pathogen, avoid harmful side effect, and should be
a very important protein for survival of the pathogen. Sup-
pression of such drug targets can result in effective control of
the pathogen without any harmful effects on the host. Our
homology-based method considers the essentiality, specific-
ity, druggability, subcellular localization, function, and
broad-spectrum condition of drug targets. Although a se-
quence similarity of the protein does not ensure the same
structures or binding properties, using such homology-based
methods could ease the optimization and production of new
drugs and vaccines. In conclusion, the homology-based
method17,20,21,32 was applied to identify novel putative drug
targets in the family Legionellaceae. The results of this study
identified several proteins in the genomes of the family Le-
gionellaceae pathogens that can be targeted for effective drug
design and development. Thus, many of these putative drug
targets that are involved in several vital metabolic pathways,
such as energy metabolism, amino acid metabolism, and lipid
metabolism, designing drug molecules against these targets
could be very effective for the treatment of Legionella in-
fections. Development of new drug against such targets will
be precise to the pathogen and considerably decrease the
harmful side effects to the host. The efficiency of already
available antimicrobial drugs can be tested using this method.
Targeting of proteins involving several essential metabolic
pathways may facilitate the efficient treatment of infections.
The findings of such studies facilitate the design and devel-
opment of novel antimicrobial drugs against the family Le-
gionellaceae and other pathogens.
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